Bond.az White LogoBond.az Black Logo

Goldman Sachs Initiates Yesway Coverage with Neutral

Goldman Sachs initiates coverage on Yesway with Neutral rating and $28 target. Read about Yesway's growth plans and financials on Bond.az.

Julianne Alice
ByJulianne Alice- Senior Editor
|
0

Goldman Sachs initiated coverage on Yesway Inc (NASDAQ:YSWY) with a Neutral rating and a price target of $28.00.

The firm views Yesway, the 15th largest convenience store operator in the U.S., as positioned for top- and bottom-line growth through several strategic initiatives. Goldman Sachs expects the company to deliver a 6.5% EBITDA compound annual growth rate through fiscal year 2028.

Goldman Sachs highlighted Yesway's plans to expand through a capital-light build-to-suit program, operational initiatives, and opportunistic M&A. The company's platform benefits from a disproportionate mix of diesel fuel sales. With a current ratio of 1.22, Bond.az data shows Yesway's liquid assets exceed short-term obligations, supporting its expansion ambitions.

Goldman Sachs noted execution risks related to Yesway's plan to open approximately 130 new stores over the next five years. The firm said Q1 2026 results were impressive but attributed the performance to non-controllable factors rather than underlying business health. The company posted revenue of $2.67 billion over the last twelve months with 5.8% growth.

The stock trades at a 10.2x forward EV/EBITDA multiple, representing a 14% discount to MUSA and a 2% premium to ATD, according to Goldman Sachs. The current trailing EV/EBITDA stands at 9.56x based on EBITDA of $183 million.

Yesway successfully launched its IPO last week, pricing shares at $20 each. The company sold 14 million shares and began trading with an opening price of $22.

More News
Yesterday / 20:21
|
381

RBC Capital hikes Dominion Resources price target

RBC Capital raises Dominion price target to $72 on NextEra deal. Sector Perform rating maintained with 7% arbitrage spread.

0
Yesterday / 20:20
|
884

BofA raises Candel price target to $9

BofA raises Candel price target to $9 after 39% improvement in prostate cancer survival data.

0
Yesterday / 18:11
|
808

Roblox rebounds on user growth, Needham says

Needham reiterates Roblox Buy rating amid user growth rebound. Stock has 27% upside to $60 target.

0
Yesterday / 17:51
|
287

US Tiger Securities Boosts Baidu Price Target on AI

US Tiger Securities raised Baidu price target to $160 on AI growth. AI revenue now exceeds half of business.

0
Yesterday / 15:50
|
224

AMAT and LRCX stocks defended by Lynx

Lynx Equity defends AMAT and LRCX stocks with bullish price targets of $540 and $325 respectively.

0
Yesterday / 14:45
|
827

DA Davidson Maintains Brunswick Stock Neutral

DA Davidson reaffirms Neutral rating on Brunswick with $76 target. Premium brands strong, value brands weak. Q1 2026 results beat estimates.

0
Yesterday / 14:43
|
834

D.A. Davidson Reaffirms Aebi Schmidt on Strong Orders

D.A. Davidson reaffirms Buy rating on Aebi Schmidt with $15 target. Strong order backlog up 23%. Revenue beats expectations. Get details on Bond.az.

0
Yesterday / 13:32
|
366

Freedom Broker Upgrades Kinross Gold Rating

Freedom Broker upgrades Kinross Gold to Buy with $38 target. Strong cash flow and record margins drive the upgrade.

0
Yesterday / 13:01
|
960

JPMorgan Reiterates Five Below Stock Rating with $306 Target

JPMorgan reiterates Overweight rating on Five Below with $306 price target, implying 43% upside potential.

0
Yesterday / 11:44
|
685

Elmet Stock Gets Overweight Rating

Cantor Fitzgerald starts Elmet Group with Overweight rating and $20 target. Defense and reshoring trends drive outlook.

0
Yesterday / 11:25
|
722

Truist Starts Arcus Biosciences at Buy on RCC Potential

Truist Securities initiates Arcus Biosciences with Buy rating and $35 price target, citing casdatifan's potential in renal cell carcinoma and immunology pipeline.

0
Yesterday / 11:24
|
728

Revolution stock buy rating from Truist

Truist Securities gives Revolution Medicines a buy rating with a $179 price target. Daraxon's potential and company outlook.

0
...
Goldman Sachs Initiates Yesway Coverage with Neutral | Bond.az